IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc., (NasdaqGM:SPPI) announced today that the Centers for Medicare and Medicaid Services (CMS), under the Medicare Part B benefit, has assigned a unique, product-specific billing code, or J-code, for FUSILEV™ (levoleucovorin). FUSILEV™ is the only commercially available formulation comprised only of the pharmacologically active isomer of leucovorin. The J-code J06410 becomes effective on January 1, 2009, and will assist providers in obtaining reimbursement for FUSILEV™.
